Fixed-dose combination therapy in pulmonary arterial hypertension: Pros & cons
Quality of life of patients suffering from chronic diseases is inevitably conditioned by the number of pills taken during the day. To improve patients' tolerability, compliance and quality of life and reduce healthcare costs, pharmaceutical companies are focusing on the commercialization of fixed-dose combination (FDC) therapies.The last ESC/ERS guidelines for the treatment of pulmonary arterial hypertension (PAH) recommend initial dual combination therapy for newly diagnosed patients at low or intermediate mortality risk.
Source: International Journal of Cardiology - Category: Cardiology Authors: Giovanna Manzi, Tommaso Recchioni, Roberto Badagliacca, Silvia Papa, Carmine Dario Vizza Source Type: research